pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News mentioning Immunology
89
stories
2d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
2d
She grew up unvaccinated. Now she’s a leading voice for science — and empathy
stat
3d
Regeneron ends eye disease study due to antibody's safety profile
biospace
3d
Regeneron ends eye disease study due to antibody's safety profile
biospace
4d
Biotech's reverse merger renaissance poised to continue
endpoints
4d
Evaxion scraps solid tumor vaccine to focus on Duke-partnered brain cancer candidate
fiercebiotech
7d
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
fiercebiotech
8d
STAT+: Eli Lilly targets booming black market for retatrutide
stat
9d
Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
fiercebiotech
9d
Boulevard Bio dreams big in immunology with $65M, sights on Vera's IgAN drug
endpoints
9d
STAT+: Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies
stat
9d
With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
biospace
9d
CytoDyn’s leronlimab reaffirms HIV potential after combo treatment eradicates virus in infant macaques
fiercebiotech
10d
Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs
fiercebiotech
10d
Epicrispr, Infinimmune snag combined $165M in VC cash
biospace
10d
Austria’s new growth fund could further bolster its dynamic biotech innovation economy
biospace
15d
Chutes & Ladders—BioNTech brings in Sobi CEO
fiercebiotech
15d
Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’
biospace
15d
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
fiercebiotech
16d
Novo CEO sees innovation as a matter of survival amid pipeline setbacks
biospace
16d
Attovia extends biotech IPO streak with $289M listing for three I&I drugs
endpoints
16d
5 NextGen winners who went public this year (and which ones are hiring)
biospace
16d
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
16d
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
fiercebiotech
17d
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
biospace
18d
BioNTech taps Sobi executive Oelkers as its next CEO
biopharma dive
18d
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
biospace
18d
Novo’s late-stage IL-6 stumble shakes inflammation space
biospace
20d
AbbVie touts strong momentum for Skyrizi despite rising competition
endpoints
21d
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
← prev
page 1 of 3
next →
